Viewing Study NCT00077961


Ignite Creation Date: 2025-12-24 @ 11:59 AM
Ignite Modification Date: 2025-12-24 @ 11:59 AM
Study NCT ID: NCT00077961
Status: TERMINATED
Last Update Posted: 2015-03-26
First Post: 2004-02-13
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Rituximab Plus CAMPATH in Patients With Relapsed/Refractory Low-Grade or Follicular, CD20-positive, B-cell NHL
Sponsor: Genzyme, a Sanofi Company
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Description Module Conditions Module Design Module Arms Interventions Module Eligibility Module Contacts Locations Module